Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53

Despite the use of multimodality therapy employing cisplatin to treat patients with advanced stage head and neck squamous cell carcinoma (HNSCC), there is an unacceptably high rate of treatment failure. TP53 is the most commonly mutated gene in HNSCC, and the impact of p53 mutation on response to ci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gadhikar, Mayur A., Sciuto, Maria Rita, Alves, Marcus Vinicius Ortega, Pickering, Curtis R., Osman, Abdullah A., Neskey, David M., Zhao, Mei, Fitzgerald, Alison L., Myers, Jeffrey N., Frederick, Mitchell J
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3955083/
https://ncbi.nlm.nih.gov/pubmed/23839309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0157
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados